Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arginine glutamate injection vs arginine hydrochloride injection in chronic liver disease with hyperammonemia
CTR20131236Phase 2Active
- Sponsor
- Furen Pharmaceutical Group
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of arginine glutamate in hyperammonemia, chronic liver disease (CLD), hepatic encephalopathy (HE), Cirrhosis, steatosis, sponsored by Furen Pharmaceutical Group. Started Nov 2013; status: active.
02
Drugs
arginine glutamate
03
Conditions
hyperammonemiachronic liver disease (CLD)hepatic encephalopathy (HE)Cirrhosissteatosis
Beyond the preview
Go deeper on CTR20131236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131236.